Please assess the completion status of the following clinical trial:

Trial Title: Study of a Live rNDV Based Vaccine Against COVID-19

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women ≥18 year-old and ≤55-year-old.~* Signed informed consent.~* No respiratory disease within last 21 days prior to first dose administration.~* Body Mass Index from 18.0 to 29.0 kg/m2.~* Negative RT-PCR for SARS-Cov-2 infection.~* Negative test for anti-SARS-CoV-2 IgM and IgG antibodies.~* O2 saturation ≥92% by pulse oximetry.~* Normal CT scan of thorax.~* No symptoms from clinical history and normal physical exam at screening visit.~* Lab test values within normal ranges for all the following:~Urinalysis. Liver enzymes. Renal function tests. Cholesterol and Triglycerides. Fasting glucose. Hematology.~* Negative test for HBsAg, anti-HCV and anti-HIV antibodies. Negative VDRL test.~* Normal electrocardiogram.~* Negative pregnancy test for women with childbearing potential.~* Agreement of all sexually- active volunteers to use highly effective contraceptives over the study period and up to 30 days after the last administration of the experimental vaccine.~* Commitment from all participants to keep social distancing, use of mask and frequent hand washing with soap or antibacterial gel during the study period.~Exclusion Criteria:~* History of hypersensitivity or allergy to any ingredient of the vaccine.~* History of severe anaphylactic reaction.~* History of seizures.~* History of chronic diseases or cancer.~* Vaccination against SARS-CoV-2 with approved or experimental vaccines.~* Participation in any other study with an experimental intervention within the last 3 months.~* Administration of any other drug or herbal preparation within the last 30 days.~* Any vaccine administered within the last 30 days, including influenza vaccine.~* Fever at the time of entry.~* Blood transfusion or blood components transfusion within the last 4 months.~* Regular activity related to work, social interaction or entertainment that represents an exposure to SARS-Cov-2 higher than that of the general population, as per investigator judgement.~* Drug and alcohol abuse.~* Any medical or not medical condition that could interfere with patient safety, study compliance or data interpretation, as per investigator judgement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Low Dose, IM-IM (Type: EXPERIMENTAL): Group 1. Dose: 10 7.0-7.49 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days.
- Intermediate dose, IM-IM (Type: EXPERIMENTAL): Group 2. Dose: 10 7.5-7.99 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days
- High dose, IM-IM (Type: EXPERIMENTAL): Group 3. Dose: 10 8.0-8.49 EID 50/dose. Both first and second administration by the intramuscular route, separated by 21 days.
- Low dose, IN-IN (Type: EXPERIMENTAL): Group 4. Dose: 10 7.0-7.49 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
- Intermediate dose, IN-IN (Type: EXPERIMENTAL): Group 5. Dose: 10 7.5-7.99 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
- High dose, IN-IN (Type: EXPERIMENTAL): Group 6. Dose: 10 8.0-8.49 EID 50/dose. Both first and second administration by the intranasal route, separated by 21 days
- Low dose, IN-IM (Type: EXPERIMENTAL): Group 7. Dose: 10 7.0-7.49 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
- Intermediate dose, IN-IM (Type: EXPERIMENTAL): Group 8. Dose: 10 7.5-7.99 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
- High dose, IN-IM (Type: EXPERIMENTAL): Group 9. Dose: 10 8.0-8.49 EID 50/dose. First administration by the intranasal route and second administration by the intramuscular route, separated by 21 days
- High dose, IM (Type: EXPERIMENTAL): Group 10. Dose: 10 8.0-8.49 EID 50/dose. 3rd administration by the intramuscular route to all the volunteers who agree to participate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete